Varian Medical Systems co-led the series B round, which will fund the development of ABK Biomedical's embolic therapies.
Cancer treatment technology provider Varian Medical Systems and F-Prime Capital, part of investment and financial services group Fidelity, have co-led a $30m series B round for Canada-based medical device developer ABK Biomedical.
Founded in 2012, ABK Biomedical is developing tiny beads designed to shrink or kill tumours by starving them of blood flow. Its technology includes Eye90 microspheres, which are designed to treat liver tumours, and Easi-Vue microspheres for hypervascular tumours.
In both cases, the microspheres can be seen by…
